{"title": "PDF", "author": "PDF", "url": "https://www.samfyc.es/wp-content/uploads/2018/08/AlertaMayo2012.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "   Mayo  2012  \nSelecci\u00f3n realizada por Antonio Manteca Gonz\u00e1lez  \n \nACADEMIC MEDICINE  \nHunt D, Migdal M, Eaglen R, Barzansky B, Sabalis R. The unintended consequences of clarity: reviewing the \nactions of the Liaison Committee on Medical Education before and after the reformatting of accreditation \nstandards. Acad Med . 2012;  87: 560-566 [QE,I]  \n22450183  RESUMEN/C ONCLUSIONES  \nCONSECUENCIAS NO BUSCADAS DE LA TRANSPARENCIA: REVISAR LAS ACCIONES DEL COMIT\u00c9 DE \nCOORDINACI\u00d3N PARA LA FORMACI\u00d3N M\u00c9D ICA ANTES Y DESPU\u00c9S DEL CAMBIO DE FORMATO DE LAS \nNORMAS DE ACREDITACI\u00d3N  \n \nWittich CM, Chutka DS, Mauck KF, Berger RA, Litin SC, Beckman TJ. Perspective: a practical approach to \ndefining professional practice gaps for continuing medical education. Acad Med . 2012;  87: 582-585 [R,II]  \n22450184  R/C   \nPERSPECTIVA: ABORDAJE PR\u00c1CTICO A LA DEFINICI\u00d3N DE LAGUNAS DE PR\u00c1CTICA PROFESIONAL \nPARA LA FORMACI\u00d3N M\u00c9DICA  CONTINUADA  \n \nANNALS OF INTERNAL MEDICINE  \n \nVan Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, et al. Tipping the balance of \nbenefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of \nrisk. Ann Intern Med . 2012;  156: 609-617 [T,II]  \n22547470  R/C \nINCLINAR LA BALANZA DE BENEFICIOS Y PERJUICIOS A FAVOR DEL CRIBAJE MAMOGR\u00c1FICO \nEMPEZANDO A LOS 40 A\u00d1OS: ESTUDIO DE MODELAJE C OMPARATIVO DE RIESGOS  \n \n \nDe Boer IH, Levin G, Robinson -Cohen C, Biggs ML, Hoofnagle AN, Siscovick DS, et al. Serum 25 -hydroxyvitamin \nD concentration and risk for major clinical disease events in a community -based population of older adults: a \ncohort study. Ann Intern Med . 2012;  156: 627-634 [S,I]  \n22547472  R/C \nCONCENTRACI\u00d3N S\u00c9RICA DE 25 -HIDROXIVITAMINA D Y RIESGO DE ENFERMEDADES IMPORTANTES \nEN UNA POBLACI\u00d3N DE ANCIANOS E N LA COMUNIDAD: ESTUDIO DE COHORTES   \n \nNelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, et al. Risk factors for breast cancer for women aged \n40 to 49 years: a systematic review and meta -analysis. Ann Intern Med . 2012;  156: 635-648 [M,II]  \n22547473  R/C \nFACTORES DE RIESGO DE C\u00c1NCER DE MAMA EN MUJERES ENTRE 40 Y 49 A\u00d1OS: REVISI\u00d3N \nSISTEM\u00c1TICA Y METAAN\u00c1LISIS  \n \nBrooks RC, Hasley PB, Jasti H, Macpherson D. Update in g eneral internal medicine: evidence published in 2011. \nAnn Intern Med . 2012;  156: 649-653 [R,I]  \n22517813  \nACTUALIZACI\u00d3N EN MEDICINA INTERNA GENERAL: EVIDENCIAS PUBLICADAS EN 2011  \n \nBrawley OW. Risk -based mammography screening: an effort to maximize the benefits and minimize the harms. \nAnn Intern Med . 2012;  156: 662-663 [AO,I]  \n22547477  \nCRIBAJE MAMOGR\u00c1FICO BASADO EN EL RIESGO: ESFUERZO PARA MAXIMIZAR L OS BENEFICIOS Y \nMINIMIZAR LOS PERJUICIOS  \n \nFan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG, Leatherman S, et al. A comprehensive care management \nprogram to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann \nIntern Med . 2012;  156: 673-683 [EC,I]  \n22586006  R/C \nPROGRAMA DE GESTI\u00d3N ASISTENCIAL INTEGRAL PARA PREVENIR LAS HOSPITALIZACIONES POR \nEPOC: ENSAYO CONTROLADO ALEATORIZAD O \n \nImperiale TF, Ransohoff DF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a \nsystematic review. Ann Intern Med . 2012;  156: 703-709 [M,II]  \n22586009  R/C    RIESGO DE C\u00c1NCER COLORRECTAL EN PERSONAS CON HISTORIA FAMILIAR DE P\u00d3LIPOS \nADENOMATOSOS: REVISI\u00d3N SISTEM\u00c1TICA  \nNeumann I, Rada G, Claro JC, Carrasco -Labra A, Thorlund K, Akl EA, et al. Oral direct factor Xa inhibitors versus \nlow-molec ular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee \nreplacement: a systematic review and meta -analysis. Ann Intern Med . 2012;  156: 710-719 [M,II]  \n22412038  R/C \nINHIBIDORES ORALES DEL FACTOR DIRECTO Xa FRENTE A HBPM PARA PREVENIR EL \nTROMBOEMBOLISMO VENOSO EN PACIENTES QUE SE SOMETEN A SUSTITUCI\u00d3N TOTAL DE CADERA O \nRODILLA: REVISI\u00d3N SISTEM\u00c1TICA Y METAAN\u00c1LISIS  \n \nARCHIVES OF INTERNA L MEDICINE  \n \nKwak SM, Myung SK, Lee YJ, Seo HG; for the Korean Meta -analysis Study Group. Efficacy of omega -3 fatty acid \nsupplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular \ndisease: a meta -analysis of r andomized, double -blind, placebo -controlled trials. Arch Intern Med . 2012 [Epub \nahead of print] [M,II]  \n22493407  R/C \nEFICACIA DE LOS SUPLEMENTOS DE \u00c1CIDOS GRASOS OMEGA -3 (\u00c1CIDO EICOSAPENTANOICO Y \u00c1CIDO \nDOCOSAHEXANOICO) EN LA PREVENCI\u00d3N SECUNDARIA DE LA ENFERMEDAD CARDIOVASCULAR: \nMETAAN\u00c1LISIS DE ENSAYOS CONTROLADOS CON PLACEBO, ALEATORIZADOS Y A DOBLE CIEGO  \n \nHu FB, Manson JE. Omega -3 fatty acids and secondary prevention of cardiovascular disease --is it just a fish \ntale?: comment on \"Efficacy of omega -3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic \nacid) in the secondary prevention of cardiovascular disease\". Arch Intern Med . 2012  [Epub ahead of print]  [AO,I]  \n22493410  \nLOS \u00c1CIDOS GRASOS OMEGA 3 Y LA PREVENCI\u00d3N SECUNDARIA DE LA ENFERMEDAD \nCARDIOVASCULAR  \u00bfES S\u00d3LO UN CUENTO DE PESCADO?*: COMENTARIO SOBRE \" EFICACIA DE LOS \nSUPLEMENTOS DE \u00c1CIDOS GRA SOS OMEGA -3 (\u00c1CIDO EICOSAPENTANOICO Y \u00c1CIDO \nDOCOSAHEXANOICO) EN LA PREVENCI\u00d3N SECUNDARIA DE LA ENFERMEDAD CARDIOVASCULAR\"  \n*Juego de palabras con la homofon\u00eda de fish tale y fishtail (cola de pescado)  \n \nARCHIVOS DE BRONCONEUMOLOGIA  \n \nPuente L, Garc\u00eda J. Las p ruebas funcionales respiratorias en las decisiones cl\u00ednicas. Arch Bronconeumol . 2012;  \n48: 161-169 [R,I]  \n22364671  R/C \nLAS PRUEBAS FUNCIONALES RESPIRATORIAS EN LAS DECI SIONES CL\u00cdNICAS   \nARTHRITIS AND RHEUMATISM  \n \nReveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH. The prevalence of HLA -B27 in the US: data from the \nUS National Health and Nutrition Examination Survey, 2009. Arthritis Rheum . 2012;  64: 1407 -1411 [T,I]  \n22139851  R/C \nPREVALENCIA DE HLA -B27 EN LOS EE UU: DATOS DE LA ENCUESTA US NATIONAL HEALTH AND \nNUTRITION EXAMINATION  \n \nWittoek R, Cruyssen BV, Verbruggen G. Predictors of  functional impairment and pain in erosive osteoarthritis of \nthe interphalangeal joints: comparison with controlled inflammatory arthritis. Arthritis Rheum . 2012;  64: 1430 -1436 \n[T,I] \n22139828  R/C \nPREDICTORES DE ALTERACI\u00d3N FUNCIONAL Y DOLOR EN LA ARTROSIS EROSIVA DE LAS \nARTICULACIONES INTERFAL\u00c1NGICAS: COMPARACI\u00d3N CON LA ARTRITIS INFLAMATORIA CONTROLADA  \n \nMuraki S, Akune T, Oka H, Ishimoto Y , Nagata K, Yoshida M, et al. I ncidence and risk factors for radiographic \nknee osteoarthritis and knee pain in Japanese men and women: a longitudinal population -based cohort study. \nArthritis Rheum . 2012;  64: 1447 -1456 [S,I]  \n2213 5156  R/C \nINCIDENCIA Y FACTORES DE RIESGO DE ARTROSIS DE RODILLA RADIOGR\u00c1FICA Y DOLOR DE RODILLA \nEN HOMBRES Y MUJERES JAPONESES: ESTUDIO DE COHORTES POBLACIONAL LONGITUDINAL  \n \nSamartzis D, Karppinen J, Chan D, Luk KD, Cheung KM . The association of lumbar intervertebral disc \ndegeneration on magnetic resonance imaging with body mass index in overweight and obese adults: a \npopulation -based study. Arthritis Rheum . 2012;  64: 1488 -1496 [T,I]  \n22287295  R/C    ASOCIACI\u00d3N DE LA DEGENERACI\u00d3N DISCAL INTERVERTEBRAL LUMBAR POR IMAGEN DE \nRESONANCIA MAGN\u00c9TICA CON EL \u00cdNDICE DE MASA CORPORAL EN ADULTOS OBESOS Y CON \nSOBREPESO: ESTUDIO POBLACIONAL  \n \nATENCION PRIMAR IA \n \nHern\u00e1ndez M\u00c1, Palacio F. La prescripci\u00f3n y los Doce Trabajos de Heracles: m\u00e1s all\u00e1 del principio activo. Aten \nPrimaria . 2012;  44: 245-247 [AO,I]  \n22546290  \nLA PRESCRIPCI\u00d3N Y LOS DOCE TRABAJOS DE  HERACLES: M\u00c1S ALL\u00c1 DEL PRINCIPIO ACTIVO  \n \nSegura A. La dimensi\u00f3n social y cultural de la prevenci\u00f3n. Aten Primaria . 2012;  44: 248-249 [AO,I]  \n22464294   \nLA DIMENSI\u00d3N SOCIAL Y CULTURAL DE LA PREVENCI \u00d3N \n \nMateos ML, Vi\u00e1n EM, Gil M, Lozano JE, Santamar\u00eda E, Herrero B. Incidencia, caracter\u00edsticas epidemiol\u00f3gicas y \ntipos de accidentes dom\u00e9sticos y de ocio. Red centinela sanitaria de Castilla y Le\u00f3n (2009) Aten Primaria . 2012;  \n44: 250-256 [T,I]  \n21733598  R/C \nINCIDENCIA, CARACTER\u00cdSTICAS EPIDEMIOL\u00d3GICAS Y TIPOS DE ACCIDENTES DOM\u00c9STICOS Y DE \nOCIO.  RED CENTINELA SANITARIA DE CASTILLA Y LE\u00d3N (2009)  \n \nArranz J, Leiva A, Carande ll E, Pujol A, M\u00e9ndez MC, Salv\u00e0 A, et al. Vigilancia sindr\u00f3mica de la gripe en atenci\u00f3n \nprimaria, un instrumento complementario a las redes centinelas para per\u00edodos de elevada incidencia de gripe. \nAten Primaria . 2012;  44: 258-264 [T,I]  \n21924796  R/C \nVIGILANCIA SINDR\u00d3MICA DE LA GRIPE EN ATENCI\u00d3N PRIMARIA, UN INSTRUMENTO COMPLEMENTARIO \nA LAS REDES CENTINELAS PARA PER\u00cdODOS DE ELEVADA INCIDENCIA DE GRIPE  \n \nMahtani -Chugani V,  L\u00f3pez -Hijazo A, Manca D, Sanz -Alvarez E. Comparando las perspectivas de los m\u00e9dicos de \natenci\u00f3n primaria de Canarias y Alberta. \u00bfEs m\u00e1s bonito el jard\u00edn del vecino que el m\u00edo? Aten Primaria . 2012;  44: \n265-271 [C,I]  \n22221963  R/C \nCOMPARANDO LAS PERSPECTIVAS DE LOS M\u00c9DICOS DE ATENCI\u00d3N PRIMARIA DE CANARIAS Y \nALBERTA.  \u00bfES M\u00c1S BONITO EL JARD\u00cdN DEL VECINO QUE EL M\u00cdO?  \n \nPacheco -Huergo V, Viladrich C, Pujol -Ribera E, Cabezas -Pe\u00f1a C, N\u00fa\u00f1ez M, Roura -Olmeda P, et al; en \nrepresentaci\u00f3n del Grupo IPQ -R. Percepci\u00f3n en enfermedades cr\u00f3nicas: validaci\u00f3n ling\u00fc\u00edstica del Illness \nPerception Questionnaire Revised y del Brief Illness Perception Questionnaire para la poblaci\u00f3n espa\u00f1ola. Aten \nPrimaria . 2012;  44: 280-287 [T,I]  \n21955598  R/C \nPERCEPCI\u00d3N EN ENFERMEDADES CR\u00d3NICAS: VALIDACI\u00d3N LING\u00dc\u00cdSTICA DEL ILLNESS PERCEPTION \nQUESTIONNAIRE REVISED Y DEL BRIEF IL LNESS PERCEPTION QUESTIONNAIRE PARA LA POBLACI\u00d3N \nESPA\u00d1OLA  \n \nVivar CG. Impacto psicosocial del c\u00e1ncer de mama en la etapa de larga supervivencia: propuesta de un plan de \ncuidados integral para supervivientes. Aten Primaria . 2012;  44: 288-292 [AO,I]  \n22019066  \nIMPACTO PSICOSOCIAL DEL C\u00c1NCER DE MAMA EN LA ETAPA DE LARGA SUPERVIVENCIA: PROPUESTA \nDE UN PLAN DE CUIDADOS INTEGRAL PARA SUPERVIVIENTES  \n \nBRITISH JOURNAL OF PSYCHIATRY  \n \nWilliams JM, Kuyken W. Mind fulness -based cognitive therapy: a promising new approach to preventing \ndepressive relapse. Br J Psychiatry . 2012;  200: 359-360 [AO,I]  \n22550328  R/C \nTERAPIA COGNITIVA BASADA E N LA PLENA CONCIENCIA: NUEVO Y PROMETEDOR ABORDAJE PARA \nPREVENIR LA RECA\u00cdDA DEPRESIVA  \n \nMorgan AJ, Jorm AF, Mackinnon AJ. Email -based promotion of self -help for subthreshold depression: Mood \nMemos randomised controlled trial. Br J Psychiatry . 2012;  200: 412-418 [EC,I]  \n22442102  R/C \nPROMOCI\u00d3N DE LA AUTOAYUDA BASADA EN EL CORREO ELECTR\u00d3NICO PARA LA DEPRESI\u00d3N \nSUBUMBRAL: ENSAYO ALEATORIZADO CONTROLADO MOOD MEMOS      \nBRITISH MED ICAL JOURNAL  \n \nBowden -Jones H, Smith N. The medical management of problem gamblers. BMJ. 2012;  344: e1559 [R,I]  \n22408265  \nMANEJO M\u00c9DICO DE LOS JUGADORES PROBLEM\u00c1TICOS  \n \nJames C. Doctors' duty to repo rt poor practice. BMJ . 2012;  344: e1695 [AO,II]  \n22427272  \nDEBER DE LOS M\u00c9DICOS DE INFORMAR DE LA PR\u00c1CTICA DEFICIENTE  \n \nGuterman L, McKee M. Severe human rights abuses in healthcare settings. BMJ. 2012; 344: e2013 [AO,I]  \n22419790  \nVIOLACIONES GRAVES DE LOS DERECHOS HUMANOS EN LOS DISPOSITIVOS DE ATENCI\u00d3N SANITARIA  \n \nVaradhan KK, Neal KR, Lobo DN. Safety and efficacy of antibiotics compared with  appendicectomy for treatment \nof uncomplicated acute appendicitis: meta -analysis of randomised controlled trials. BMJ. 2012;  344: e2156 [M,II]  \n22491789  R/C \nSEGURIDAD Y EFICAC IA DE LOS ANTIBI\u00d3TICOS EN COMPARACI\u00d3N CON LA APENDICECTOM\u00cdA EN EL \nTRATAMIENTO DE LA APENDICITIS AGUDA NO COMPLICADA: METAAN\u00c1LISIS DE ENSAYOS \nCONTROLADOS ALEATORIZADOS  \n \nNair H, Holmes A, Rudan I, Car J. Influenza vaccination in healthcare professionals. BMJ. 2012;  344: e2217 [R,I]  \n22457439  \nVACUNACI\u00d3N CONTRA LA GRIPE EN PROFESIONALES SANITARIOS  \n \nBakker OJ. Should conservative treatment of appendicitis be first line? BMJ. 2012;  344: e2546 [AO,I]  \n22491791  \n\u00bfDEBER\u00cdA SER DE PRIMERA L\u00cdNEA EL TRATAMIENTO CONSERVADOR DE LA APENDICITIS?  \n \nMerry SN, Stasiak K, Shepherd M, Frampton C, Fleming T, Lucassen MF. The effectiveness of SPARX, a \ncomputerised sel f help intervention for adolescents seeking help for depression: randomised controlled non -\ninferiority trial. BMJ. 2012;  344: e2598 [EC,II]  \n22517917  R/C \nEFECTIVIDAD D E SPARX, INTERVENCI\u00d3N INFORMATIZADA DE AUTOAYUDA PARA ADOLESCENTES QUE \nBUSCAN AYUDA PARA LA DEPRESI\u00d3N: ENSAYO CONTROLADO DE NO INFERIORIDAD ALEATORIZADO  \n \nFisher HL, Moffitt TE, Houts RM, Belsky DW, Arseneault L, Caspi A. Bullying victimisation and risk of self harm in \nearly adolescence: longitudinal cohort study. BMJ. 2012;  344: e2683 [S,I]  \n22539176  R/C \nPERSECUCI\u00d3N Y ACOSO ESCOLAR Y RIESGO DE AUTOLESIONES EN LA ADOLESC ENCIA TEMPRANA: \nESTUDIO DE COHORTES LONGITUDINAL  \n \nPoston L, Chappell LC. How should women be advised on weight management in pregnancy? BMJ. 2012;  344: \ne2774 [R,I]  \n22596384  \n\u00bfC\u00d3MO SE DEBER\u00cdA ACONSE JAR A LAS MUJERES SOBRE EL MANEJO DEL PESO  DURANTE EL \nEMBARAZO?  \n \nPasternak B, Svanstr\u00f6m H, M\u00f8lgaard -Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Vaccination against \npandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ. 2012;  344: \ne2794 [S,II]  \n22551713  R/C \nVACUNACI\u00d3N CONTRA LA GRIPE PAND\u00c9MICA A/H1N1 DEL 2009 EN EL EMBARAZO Y RIESGO DE \nMUERTE FETAL: ESTUDIO DE COHORTES E N DINAMARCA  \n \nBennett MI, Graham J, Schmidt -Hansen M, Prettyjohns M, Arnold S; On behalf of the Guideline Development \nGroup. Prescribing strong opioids for pain in adult palliative care: summary of NICE guidance. BMJ. 2012;  344: \ne2806 [M,II]  \n22623631  \nPRESCRIPCI\u00d3N DE OPIOIDES FUERTES PARA EL DOLOR EN CUIDADOS PALIATIVOS EN ADULTOS: \nRESUMEN DE LA GU\u00cdA NICE  \n \nFarrell M, Wodak A, Gowing L. Maintenance drugs to treat opioid dependence. BMJ. 2012;  344: e2823 [R,I]     22589497  \nF\u00c1RMACOS DE MANTENIMIENTO PARA TRATAR LA DEPENDENCIA DE OPIOIDES  \n \nProchaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for \ntobac co cessation: systematic review and meta -analysis. BMJ. 2012;  344: e2856 [M,II]  \n22563098  R/C \nRIESGO DE ACONTECIMIENTOS CARDIOVASCULARES GRAVES ASOCIADOS CON EL USO DE  LA \nVARENICILINA PARA EL ABANDONO TAB\u00c1QUICO: REVISI\u00d3N SISTEM\u00c1TICA Y METAAN\u00c1LISIS  \n \nBartley M. Economic inactivity and health. BMJ. 2012;  344: e2858 [AO,I]  \n22573648  \nINACTIVIDAD ECON\u00d3MICA Y SALUD  \n \nRodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ. 2012;  \n344: e2986 [R,I]  \n22550350  \nINHIBIDORES DE LA COLINESTERASA Y MEMANTINA PARA ELTRATAMIENTO SINTOM\u00c1TICO DE LA \nDEMENCIA  \n \nKhan KS, Champaneria R, Latthe PM. How effective are non -drug, non -surgical treatments for primary \ndysmenorrhoea? BMJ. 2012;  344: e3011 [R,I]  \n22586231  \n\u00bfCU\u00c1N EFECTIVOS S ON LOS TRATAMIENTOS NO FARMACOL\u00d3GICOS Y NO QUIR\u00daRGICOS EN LA \nDISMENORREA PRIMARIA?  \n \nLeschziner G, Gringras P. Restless legs syndrome. BMJ. 2012 ; 344: e3056 [R,I]  \n22623643  \nS\u00cdNDROME DE PIERNAS INQUI ETAS  \n \nKnight M, Lim B. Immunisation against influenza during pregnancy. BMJ. 2012;  344: e3091 [AO,I]  \n22551717  \nINMUNIZACI\u00d3N CONTRA LA GRIPE DURANTE EL EMBARAZO  \n \nCollins GS, Moons KG. Comparing risk  prediction models. BMJ. 2012;  344: e3186 [AO,I]  \n22628131  \nCOMPARAR LOS MODELOS DE PREDICCI\u00d3N DE RIESGO  \n \nSiontis GC, Tzoulaki I, Siontis KC, Ioannidis JP. Comparisons of established risk prediction  models for \ncardiovascular disease: systematic review. BMJ. 2012;  344: e3318 [M,II]  \n22628003  R/C \nCOMPARACIONES DE LOS MODELOS ESTABLECIDOS DEPREDICCI\u00d3N DE RIESGO EN L A ENFERMEDAD \nCARDIOVASCULAR: REVISI\u00d3N SISTEM\u00c1TICA  \n \nCANADIAN MEDICAL ASSOCIATION JOURNAL  \n \nAlmadi MA, Barkun JS, Barkun AN. Management of suspected stones in the common bile duct. CMAJ . 2012;  184: \n884-892 [R,I]  \n22508980  \nMANEJO DE LA SOSPECHA DE C\u00c1LCULOS EN EL CONDUCTO BILIAR  \n \nKiddoo DA. Nocturnal enuresis. CMAJ . 2012;  184: 908-911 [AO,I]  \n22529169  \nENURESIS NOCTURNA  \n \nMann R, Adamson J, Gilbody  SM. Diagnostic accuracy of case -finding questions to identify perinatal depression. \nCMAJ . 2012;  184: E424 -E430 [T,I]  \n22451686  R/C \nEXACTITUD DIAGN\u00d3STICA DE LAS PREGUN TAS DE DETECCI\u00d3N DE CASOS PARA IDENTIFICAR LA \nDEPRESI\u00d3N PERINATAL  \n \nEtminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: \na retrospective cohort study. CMAJ . 2012;  184: E431 -E434 [S,I]  \n22470169  R/C    EFECTOS ADVERSOS OCULARES INFLAMATORIOS CON EL USO DE BIFOSFONATOS ORALES: ESTUDIO \nDE COHORTES RETROSPECTIVO  \n \nCIRCULATION  \n \nWhite RH. Identifying risk factors for venous thromboembolism. Circulation . 2012;  125: 2051 -2053 [AO,I]  \n22474263  \nIDENTIFICAR FACTORES DE RIESGO DE TROMBOEMBOLISMO VENOSO  \n \nPikula A, Beiser AS, Decarli C, Himali JJ, Debette S, Au R, et al. Mult iple biomarkers and risk of clinical and \nsubclinical vascular brain injury: the Framingham offspring study. Circulation . 2012;  125: 2100 -2107 [S,II]  \n22456473  R/C \nBIOM ARCADORES M\u00daLTIPLES Y RIESGO DE DA\u00d1O VASCULAR CEREBRAL CL\u00cdNICO Y SUBCL\u00cdNICO: \nESTUDIO DE DESCENDENCIA DE FRAMINGHAM  \n \nColman E. Food and Drug Administration's obesity drug guidance document: a short history. Circulation . 2012;  \n125: 2156 -2164 [AO,II]  \n22547756  \nDOCUMENTO DE LA FDA DE GU\u00cdA DE F\u00c1RMACOS PARA LA OBESIDAD: BREVE HISTORIA  \n \nFuster V, Chinitz JS. Net clinical benefit of warfarin: extending the reach of antithrombotic therapy for atrial \nfibrilla tion. Circulation . 2012;  125: 2285 -2287 [AO,I]  \n22514253  \nBENEFICIO CL\u00cdNICO NETO DE LA WARFARINA: EXTENDER EL ALCANCE DE LA TERAPIA \nANTITROMB\u00d3TICA DE LA FIBRILACI\u00d3N AURICULAR  \n \nFriberg L, Rosenqvist M, Lip GY . Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the \nSwedish atrial fibrillation cohort study. Circulation . 2012;  125: 2298 -2307 [S,I]  \n22514252  R/C \nBENEFICIO CL\u00cdNI CO DE LA WARFARINA EN PACIENTES CON FIBRILACI\u00d3N AURICULAR: INFORME DEL \nESTUDIO DE COHORTES SUECO SOBRE FIBRILACI\u00d3N AURICULAR  \n \nTopjian AA, Berg RA. Pediatric out -of-hospital cardiac arrest. Circulation . 2012;  125: 2374 -2378 [AO,I]  \n22586292  \nPARADA CARDIACA PEDI\u00c1TRICA EXTRAHOSPITALARIA  \n \nParish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, et al; on behalf of the Heart Protection Study \nCollaborative G roup. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart \nProtection study. Circulation . 2012;  125: 2469 -2478 [EC,II]  \n22539783   R/C \nL\u00cdPIDOS Y LIPOPROTE\u00cdNAS Y RIESGO DE DISTINTOS ACONTECIMIENTOS EN EL ESTUDIO DE \nPROTECCI\u00d3N CARDIACA MRC/BHF  \n \nLockhart PB, Bolger AF, Papapanou PN, Osinbowale O, Trevisan M, Levison ME, et al; on behalf of the American \nHeart Association Rheumatic Fever, Endocar ditis, and Kawasaki Disease Committee of the Council on \nCardiovascular Disease in the Young, Council on Epidemiology and Prevention, Council on Peripheral Vascular \nDisease, and Council on. Periodontal disease and atherosclerotic vascular disease: does the evidence support an \nindependent association?: a scientific statement from the American Heart Association. Circulation . 2012;  125: \n2520 -2544 [M,II]  \n22514251   R/C \nENFER MEDAD PERIODONTAL Y ENFERMEDAD VASCULAR ATEROSCLER\u00d3TICA: \u00bfRESPALDA LA \nEVIDENCIA UNA ASOCIACI\u00d3N INDEPENDIENTE?: DECLARACI\u00d3N CIENT\u00cdFICA DE LA AHA  \n \nDIABETES CARE  \n \nKirkman MS, Schaffner W. Another shot to protect people with diabetes: add hepatitis B vaccinati on to the \nchecklist. Diabetes Care . 2012;  35: 941-942 [AO,I]  \n22517936   \nOTRO INTENTO PARA PROTEGER A LAS PERSONAS CON DIABETES: A\u00d1ADIR LA VACUNA DE LA \nHEPATITIS B A LA LISTA  \n \nHerman WH, Zimmet P. T ype 2 diabetes: an epidemic requiring global attention and urgent action. Diabetes Care . \n2012;  35: 943-944 [AO,I]  \n22517937     DIABETES TIPO2: UNA EPIDEMIA QUE REQUIERE ATENCI\u00d3N MUNDIAL Y ACTUACI\u00d3N UR GENTE  \n \nvan Dijk JW, Tummers K, Stehouwer CD, Hartgens F, van Loon LJ. Exercise therapy in type 2 diabetes: is daily \nexercise required to optimize glycemic control? Diabetes Care . 2012;  35: 948-954 [EC,I]  \n22399700  R/C \nTERAPIA DE EJERCICIO EN LA DIABETES TIPO 2 : \u00bfSE NECESITA EJERCICIO DIARIAMENTE PARA \nOPTIMIZAR EL CONTROL GLUC\u00c9MICO?  \n \nDunstan DW, Kingwell BA, Larsen R, Healy GN, Cerin E, Hamilton MT, et al. Breaking up pr olonged sitting \nreduces postprandial glucose and insulin responses. Diabetes Care . 2012;  35: 976-983 [EC,II]  \n22374636   R/C \nROMPER CON LA SEDESTACI\u00d3N PROLONGADA REDUCE  LA GLUCOSA POSTPRANDIAL Y LAS \nRESPUESTAS A LA INSULINA  \n \nHeianza Y , Arase Y , Fujihara K, Hsieh SD, Saito K, Tsuji H, et al. Longitudinal trajectories of HbA1c and fasting \nplasma glucose levels during the development of type 2 diabetes: the Toranomon Hospit al Health Management \nCenter Study 7 (TOPICS 7). Diabetes Care . 2012;  35: 1050 -1052 [S,II]  \n22456865  R/C \nTRAYECTORIAS LONGITUDINALES DE LOS NIVELES DE GLUCOSA PLASM\u00c1TIC A EN AYUNAS Y DE \nHBA1C DURANTE EL DESARROLLO DE LA DIABETES TIPO 2: ESTUDIO TOPICS 7  \n \nTseng PH, Lee YC, Chiu HM, Chen CC, Liao WC, Tu CH, et al. Association of diabetes and HbA1c levels with \ngastrointestinal manifestations. Diabetes Care . 2012;  35: 1053 -1060 [T,I]  \n22410812  R/C \nASOCIACI\u00d3N DE DIABETES Y NIVELES DE HBA1C CON MANIFESTACIONES GASTROINTESTINALES  \n \nWilliams ED, Rawal L, Oldenburg BF, Renwick C, Shaw JE, Tapp R J. Risk of cardiovascular and all -cause \nmortality: impact of impaired health -related functioning and diabetes: the Australian Diabetes, Obesity and \nLifestyle (AusDiab) study. Diabetes Care . 2012;  35: 1067 -1073 [S,II]  \n22446177   R/C \nRIESGO DE MORTALIDAD CARDIOVASCULAR Y POR CUALQUIER OTRA CAUSA: IMPACTO DE LA \nFUNCIONALIDAD RELACIONADA CON ALTERACI\u00d3N DE LA SALUD Y DE LA DIABETES: ESTUDIO AUSDIAB  \n \nThomas GN, O Hartaigh B, Bosch JA, Pilz S, Loerbroks A, Kleber ME, et al. Vitamin D levels predict all -cause and \ncardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen Risk and \nCardiovascular Health (LURIC) study. Diabetes Care . 2012;  35: 1158 -1164 [S,II]  \n22399697  R/C \nLOS NIVELES DE VITAMINA D PREDICEN LA MORTALIDAD POR ENFERMEDAD CARDIOVASCULAR Y POR \nCUALQUIER OTRA CAUSA EN SUJETOS CON S\u00cdNDROME METAB\u00d3LICO: ESTUDIO LURIC  \n \nBest JD, Drury PL, Davis TM, Taskinen MR, Kes\u00e4niemi YA, Scott R, et al; on behalf of the Fenofibrate \nIntervention and Event Lowering in Diabetes (FIELD) Study Investigators. Glycemic control over 5 years in 4,900 \npeople with type 2 diabetes:  real-world diabetes therapy in a clinical trial cohort. Diabetes Care . 2012;  35: 1165 -\n1170 [S,II]  \n22432105  R/C \nCONTROL GLUC\u00c9MICO A LO LARGO DE 5 A\u00d1OS EN 4.900 PERSON AS CON DIABETES TIPO 2: \nTRATAMIENTO DE LA DIABETES EN EL ENTORNO REAL EN UN ENSAYO CL\u00cdNICO DE COHORTES  \n \nPan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, et al. Bidirectional association between depression \nand metabolic syndrome: a systematic review and meta -analysis of epidemiological studies. Diabetes Care . 2012;  \n35: 1171 -1180 [M,I]  \n22517938  R/C \nASOCIACI\u00d3N BIDIRECCIONAL ENTRE DEPRESI\u00d3N Y S\u00cdNDROME METAB\u00d3LICO: RE VISI\u00d3N SISTEM\u00c1TICA \nY METAAN\u00c1LISIS DE ESTUDIOS EPIDEMIOL\u00d3GICOS  \n \nDRUGS  \n \nRoth SH. Coming to terms with nonsteroidal anti -inflammatory drug gastropathy. Drugs . 2012;  72: 873-879 [R,I]  \n22564130  R/C \nPONE RSE DE ACUERDO EN CUANTO A LA GASTROPAT\u00cdA POR AINE  \n \nStewart SE, Hezel D, Stachon AC. Assessment and medication management of paediatric obsessive -compulsive \ndisorder. Drugs . 2012;  72: 881-893 [R,II]  \n22564131  R/C    VALORACI\u00d3N Y MANEJO DE LA MEDICACI\u00d3N EN EL TRASTORNO OBSESIVO -COMPULSIVO PEDI\u00c1TRICO  \n \nEUROPEAN HEART JOURNAL  \n \nSwedberg K, Komajda M. The beat goes on: on the importance of heart rate in chronic heart failure. Eur Heart J . \n2012;  33: 1044 -1045 [AO,I]  \n22408032  \nEL LATIDO CONTIN\u00daA: SOBRE LA IMPORTANCIA DE LA FRECUENCIA CARDIACA EN LA INSUFICIENCIA \nCARDIACA CR\u00d3NICA  \n \nParati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur \nHeart J . 2012;  33: 1058 -1066 [R,I]  \n22507981  R/C \nEL SISTEMA NERVIOSO SIMP\u00c1TICO HUMANO: SU RELEVANCIA EN LA HIPERTENSI\u00d3N Y LA \nINSUFIC IENCIA CARDIACA  \n \nShould we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. \nEur Heart J . 2012;  33: 1137 -1141 [AO,I]  \n22408030  R/C \n\u00bfDEBER\u00cdAMOS CAMBIAR (SHIFT, por el estudio SHIFT) NUESTRA FORMA DE PENSAR RESPECTO A LA \nDIGOXINA?  OBSERVACIONES SOBRE LA IVABRADINA Y LA REDUCCI\u00d3N DE LA FRECUENCIA CARDIACA \nEN LA INSUFICIENCIA CARDIACA  \n \nGurbel PA, Ohman EM, Jeong YH, Tantr y US. Toward a therapeutic window for antiplatelet therapy in the elderly. \nEur Heart J . 2012;  33: 1187 -1189 [R,I]  \n22270540  \nHACIA UNA VENTANA TERAP\u00c9UTICA EN LA TERAPIA ANTIPLAQUETARIA EN LOS ANCIANO S \n \nBhatia LS, Curzen NP, Calder PC, Byrne CD. Non -alcoholic fatty liver disease: a new and important \ncardiovascular risk factor? Eur Heart J . 2012;  33: 1190 -1200 [R,I]  \n22408036  R/C \nENFERMEDAD DE H\u00cdGADO GRASO NO ALCOH\u00d3LICO: \u00bfUN NUEVO E IMPORTANTE FACTOR DE RIESGO \nCARDIOVASCULAR?  \n \nFAMILY MEDICINE  \n \nGreen MJ , Masters  R, James B, Simmons B, Lehman E. Do gifts from the pharmaceutical industry affect trust in \nphysicians? Fam M ed. 2012;  44: 325-331 [T,I]  \n R/C \n\u00bfAFECTAN A LA CONFIANZA EN LOS M\u00c9DICOS LOS REGALOS DE LA INDUSTRIA FARMAC\u00c9UTICA?  \n \nReilly JM, Gravdal JA. An ecological model for family violence prevention across the life cycle. Fam Med . 2012;  \n44: 332-335 [R,I]  \nMODELO ECOL\u00d3GICO PARA LA PREVENCI\u00d3N DE LA VIOLENCIA FAMILIAR DURANTE EL CICLO VITAL  \n \nKruse RL, Koopman RJ, Wakefield BJ, Wakefield DS, Keplinger LE, Canfield SM, et al. Internet use by primary \ncare patients: where is the digital divide? Fam Med . 2012;  44: 342-347 [T,I]  \n R/C \nUSO DE INTERNET POR LOS PACIENTES DE ATENCI\u00d3N PRIMARIA: \u00bfD\u00d3NDE EST\u00c1 LA DIVISORIA \nDIGITAL?  \n \nGeorge P, Reis S, Nothnagle M. Using a learning coach to teach residents evidence -based medicine. Fam Med . \n2012;  44: 351-355 [QE,I]  \n R/C \nUSAR UN MONITOR DE APRENDIZAJE PARA ENSE\u00d1AR A LOS RESIDENTES LA MEDICINA BASADA EN LA \nEVIDENCIA  \n \nGUT  \n \nJanssen HL, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface  antigen: is it useful for the \nmanagement of chronic hepatitis B? Gut. 2012;  61: 641-645 [AO,I]  \n22180061  \nCUANTIFICACI\u00d3N DEL ANT\u00cdGENO DE SUPERFICIE DE LA HEPATITIS B: \u00bfES \u00daTIL EN EL MANEJO DE LA \nHEPATITIS B CR\u00d3NICA?      \nMalfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al; The European Helicobacter Study \nGroup (EHSG). Management of Helicobacter pylori infection --the Maastricht IV/ Florence Consensus Report. Gut. \n2012;  61: 646-664 [M,II]  \n22491499  R/C \nMANEJO DE LA INFECCI\u00d3N POR HELICOBACTER PYLORI --INFORME DE CONSENSO MAASTRICHT \nIV/FLORENCIA  \n \nJOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE  \n \nDumont IP, Olson AL. Primary care, depression, and anxiety: exploring somatic and emotional predictors of \nmental health status in adolescents. J Am Board Fam Med . 2012;  25: 291-299 [T,I]  \n22570392  R/C \nATENCI\u00d3N PRIMARIA, DEPRESI\u00d3N Y ANSIEDAD: EXPLORAR LOS PREDICTORES SOM\u00c1TICOS Y \nEMOCIONALES DEL ESTADO DE SALUD MENTAL EN ADOLESCENTES  \n \nSadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems  in dementia. J \nAm Board Fam Med . 2012;  25: 350-366 [M,II]  \n22570399  R/C \nPAUTAS PARA EL MANEJO DE LOS PROBLEMAS COGNITIVOS Y CONDUCTUALES EN LA DEMENCIA  \n \nGalvin JE, Sad owsky CH. Practical guidelines for the recognition and diagnosis of dementia. J Am Board Fam \nMed. 2012;  25: 367-382 [M,II]  \n22570400  R/C \nGU\u00cdAS PR\u00c1CTICAS PARA EL RECONOC IMIENTO Y DIAGN\u00d3STICO DE LA DEMENCIA  \n \nJOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  \n \nCassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. \nJAMA . 2012;  307: 1801 -1802 [AO,I]  \n22492759  \nESCOGER CON DISCERNIMIENTO: AYUDAR A LOS M\u00c9DICOS Y A LOS PACIENTES A TOMAR DECISIONES \nINTELIGENTES SOBRE SU ATENCI\u00d3N  \n \nChristian P, Black RE. Food, micronutrients, and birth outcomes. JAMA . 2012;  307: 2094 -2096 [AO,I]  \n22665110  \nCOMIDA, MICRONUTRIENTES Y RESULTADOS EN EL NACIMIENTO  \n \nMEDICINA CLINICA  \n \nP\u00e9rez A, Franch J, Cases A, Gonz\u00e1lez JR, Conthe P, Gimeno E, et al. Relaci\u00f3n del grado de control gluc\u00e9mico \ncon la s caracter\u00edsticas de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES. \nMed Clin (Barc) . 2012;  138: 505-511 [T,II]  \n22118974   R/C \nRELACI\u00d3N DEL GRADO DE CONTROL GLUC\u00c9MICO CON LAS CARACTER\u00cdSTICAS DE LA DIABETES Y EL \nTRATAMIENTO DE LA HIPERGLUCEMIA EN LA DIABETES TIPO 2.  ESTUDIO DIABES  \n \nLlisterri JL, Barrios V, de la Sierra A, Escobar C, Gonz\u00e1lez -Segura D. Prevalencia de enfermedad rena l cr\u00f3nica \nen mujeres hipertensas de edad avanzada atendidas en atenci\u00f3n primaria. Estudio MERICAP. Med Clin (Barc) . \n2012;  138: 512-518 [T,I]  \n21944650   R/C \nPREVALENCIA  DE ENFERMEDAD RENAL CR\u00d3NICA EN MUJERES HIPERTENSAS DE EDAD AVANZADA \nATENDIDAS EN ATENCI\u00d3N PRIMARIA  \n \nSoriguer F, Ruiz de Adana MS. Calidad de la asistencia a los pacientes con diabetes mellitus tipo 2 en Espa\u00f1a. \nMed Clin (Barc) . 2012;  138: 522-524 [AO,I]  \n22118976   \nCALIDAD DE LA ASISTENCIA A LOS PACIENTES CON DIABETES MELLITUS TIPO 2 EN ESPA\u00d1A  \n \nCalatrava M, L\u00f3pez -Del Burgo C, de Irala J. Factores de riesgo relacionados con la salud sexual en los j\u00f3v enes \neuropeos. Med Clin (Barc) . 2012;  138: 534-540 [R,I]  \n22015005   R/C \nFACTORES DE RIESGO RELACIONADOS CON LA SALUD SEXUAL EN LOS J\u00d3VENES EUROPEOS  \n    Garc\u00eda -Donaire JA,  Dalf\u00f3 A, Sanclemente C, Urdiales D, Mart\u00ednez F, Ortega N, et al. Medida de la presi\u00f3n arterial \nen consulta y automatizada (BPTru\u00ae) para evaluar el efecto de bata blanca. Med Clin (Barc) . 2012;  138: 597-601 \n[EC,I]  \n22440145   R/C \nMEDIDA DE LA PRESI\u00d3N ARTERIAL EN CONSULTA Y AUTOMATIZADA (BPTRU\u00ae) PARA EVALUAR EL \nEFECTO DE BATA BLANCA  \n \nQuir\u00f3s R, Garc\u00eda J, Mart\u00edn MD, Trujillo J, Villena M\u00c1, Perea E. Factores pron\u00f3sticos y su pervivencia a largo plazo \ntras el diagn\u00f3stico inicial de insuficiencia cardiaca. Med Clin (Barc) . 2012;  138: 602-608 [S,I]  \n21663923   R/C \nFACTORES PRON\u00d3STICOS Y SUPERV IVENCIA A LARGO PLAZO TRAS EL DIAGN\u00d3STICO INICIAL DE \nINSUFICIENCIA CARDIACA  \n \nClua-Espuny JL, Pi\u00f1ol -Moreso JL, Gil -Guill\u00e9n FV, Orozco -Beltran D, Panisello -Tafalla A, Lucas -Noll J. La atenci\u00f3n \nsanitaria del ictus en el \u00e1rea Terres de l\u2019Ebre desde la implanta ci\u00f3n del C\u00f3digo Ictus: Estudio Ebrictus. Med Clin \n(Barc) . 2012;  138: 609-611 [S,II]  \n22153783   R/C \nLA ATENCI\u00d3N SANITARIA DEL ICTUS EN EL \u00c1REA TERRES DE L\u2019EBRE DESDE LA  IMPLANTACI\u00d3N DEL \nC\u00d3DIGO ICTUS: ESTUDIO EBRICTUS  \n \nCamafort M, Coca A. Medir apropiadamente la presi\u00f3n arterial. \u00bfCuesti\u00f3n de precisi\u00f3n o de simplicidad? Med \nClin (Barc) . 2012;  138: 612-613 [AO,I]  \n22440142   \nMEDIR APROPIADAMENTE LA PRESI\u00d3N ARTERIAL.  \u00bfCUESTI\u00d3N DE PRECISI\u00d3N O DE SIMPLICIDAD?  \n \nRuano -Ravina A. Sociedades cient\u00edficas y su relaci\u00f3n econ\u00f3mica con la industria. Situaci\u00f3n en Espa\u00f1a. Med Clin \n(Barc) . 2012;  138: 614-616 [AO,I]  \n22440141   \nSOCIEDADES CIENT\u00cdFICAS Y SU RELACI\u00d3N ECON\u00d3MICA CON LA INDUSTRIA.  SITUACI\u00d3N EN ESPA\u00d1A  \n \nBol\u00edbar B, Fina F, Morros R, Garcia -Gil MdM, Hermosilla E, Ramos R, et al; en representaci\u00f3n del Grupo SIDIAP. \nBase d e datos SIDIAP: la historia cl\u00ednica informatizada de Atenci\u00f3n Primaria como fuente de informaci\u00f3n para la \ninvestigaci\u00f3n epidemiol\u00f3gica. Med Clin (Barc) . 2012;  138: 617-621 [R,I]  \n22444996   \nBASE DE DATOS SIDIAP: LA HISTORIA CL\u00cdNICA INFORMATIZADA DE ATENCI\u00d3N PRIMARIA COMO \nFUENTE DE INFORMACI\u00d3N PARA LA INVESTIGACI\u00d3N EPIDEMIOL\u00d3GICA  \n \nRevuelta G. Salud en Espa\u00f1a durante el per\u00edodo 2000 -2009: aproximaci\u00f3n a trav\u00e9s del an\u00e1lisis de la prensa. Med \nClin (Barc) . 2012;  138: 622-626 [R,I]  \n21621230   \nSALUD EN ESPA\u00d1A DURANTE EL PER\u00cdODO 2000 -2009: APROXIMACI\u00d3N A TRAV\u00c9S DEL AN\u00c1LISIS DE LA \nPRENSA  \n \nFuster D, Tor J, Rey -Joly C, Muga R. Interacciones patog\u00e9nicas e ntre alcohol y hepatitis C. Med Clin (Barc) . \n2012;  138: 627-632 [R,I]  \n21696783   \nINTERACCIONES PATOG\u00c9NICAS ENTRE ALCOHOL Y HEPATITIS C  \n \nGrau -Amor\u00f3s J, Formiga F, Aramburu O, Recio -Iglesias J, Trull \u00e0s JC, Urrutia A. Anemia en la insuficiencia \ncardiaca: su utilidad como marcador de pron\u00f3stico o de comorbilidad: estudio GESAIC -2. Med Clin (Barc) . 2012;  \n138: 656-659 [S,II]  \n22397982  R/C \nANEMIA EN LA INSUFICIENCIA CARDIACA: SU UTILIDAD COMO MARCADOR DE PRON\u00d3STICO O DE \nCOMORBILIDAD: ESTUDIO GESAIC -2 \n \nCaminero JA. Tuberculosis multirresistente. Med Clin (Barc) . 2012;  138: 660-662 [AO,I]  \n22401731   \nTUBERCULOSIS MULTIRRESISTENTE  \n \nSopena N. Higiene de manos para una atenci\u00f3n m\u00e1s segura. Med Clin (Barc) . 2012;  138: 663-665 [AO,I]  \n22459576   \nHIGIENE DE MANOS P ARA UNA ATENCI\u00d3N M\u00c1S SEGURA  \n \nP\u00e9rez A, G\u00f3mez R, Alvarez F, Garc\u00eda J, Mediavilla JJ, Men\u00e9ndez E. Documento de consenso sobre el \ntratamiento al alta hospitalaria del paciente con hiperglucemia. Med Clin (Barc) . 2012;  138: 666.e1 -e10 [M,II]     22503128   R/C \nDOCUMENTO DE CONSENSO SOBRE EL TRATAMIENTO AL ALTA HOSPITALARIA DEL PACIENTE CON \nHIPERGLUCEMIA  \n \nRoca -Cusachs A; en nombre del Grupo de trabajo sobre hipertensi\u00f3n arterial y pol\u00edtica de salud en Catalu\u00f1a. \nHipertensi\u00f3n arterial y pol\u00edtica de salud en Catalu\u00f1a: de la teor\u00eda a la pr\u00e1ctica. Med Clin (Barc) . 2012;  138: 678-\n683 [R,I]  \n22197367   \nHIPERTENSI\u00d3N ARTERIAL Y POL\u00cd TICA DE SALUD EN CATALU\u00d1A: DE LA TEOR\u00cdA A LA PR\u00c1CTICA  \n \nREUMATOLOGIA CLINICA  \n \nPueyo MJ, Larrosa M, Sur\u00eds X, Garcia -Ruiz AJ. An\u00e1lisis de coste -utilidad e impacto presupuestario de la \nprevenci\u00f3n primaria con alendronato de la fractura osteopor\u00f3tica de cadera en Catalu\u00f1a. Reumatol Clin .  2012;  8: \n128-134 [CE,II]  \n22421456  R/C \nAN\u00c1LISIS DE COSTE -UTILIDAD E IMPACTO PRESUPUESTARIO DE LA PREVENCI\u00d3N PRIMARIA CON \nALENDRONATO DE LA  FRACTURA OSTEOPOR\u00d3TICA DE CADERA EN CATALU\u00d1A  \n \nRomero CM, Manrique S, Rodr\u00edguez M. Marcadores bioqu\u00edmicos en osteoporosis. Utilidad en la pr\u00e1ctica cl\u00ednica.  \nReumatol Clin .  2012;  8: 149-152 [R,I]  \n22089065  R/C \nMARCADORES BIOQU\u00cdMICOS EN OSTEOPOROSIS.  UTILIDAD EN LA PR\u00c1CTICA CL\u00cdNICA  \n \nREVISTA ESPA\u00d1OLA DE CARDIOLOGIA  \n \nVrints CJ. Mejora de la calidad de la asistencia en el infarto agudo de miocardio: es necesario prestar may or \natenci\u00f3n al tratamiento m\u00e9dico \u00f3ptimo a largo plazo y a la prevenci\u00f3n secundaria. Rev Esp Cardiol . 2012;  65: \n401-402 [AO,I]  \n22425437  \nMEJORA DE LA CALIDAD DE LA ASISTENCIA EN EL INFARTO AGUDO DE  MIOCARDIO: ES NECESARIO \nPRESTAR MAYOR ATENCI\u00d3N AL TRATAMIENTO M\u00c9DICO \u00d3PTIMO A LARGO PLAZO Y A LA PREVENCI\u00d3N \nSECUNDARIA  \n \nSrikanthan P, Horwich TB. La paradoja de la obesidad: es hora de adoptar una perspectiva nueva sobre un \nparadigma antiguo. Rev Esp Card iol. 2012;  65: 403-404 [AO,I]  \n22406399  \nLA PARADOJA DE LA OBESIDAD: ES HORA DE ADOPTAR UNA PERSPECTIVA NUEVA SOBRE UN \nPARADIGMA ANTIGUO  \n \nTHE LANCET  \n \nBlum RW, Bastos FI, Kabiru CW, Le LC. Adolescent  health in the 21st century. Lancet . 2012;  379: 1567 -1568 \n[AO,I]  \n22538177   \nSALUD DEL ADOLESCENTE EN ELSIGLO 21  \n \nRothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspiri n on risk of cancer \nmetastasis: a study of  incident cancers during randomised controlled trials. Lancet . 2012;  379: 1591 -1601 [M,II]  \n22440947   R/C \nEFECTO DE LA ASPIR INA DIARIA SOBRE EL RIESGO DE MET\u00c1STASIS DE C\u00c1NCER: ESTUDIO DE \nINCIDENCIA DE C\u00c1NCERES DURANTE ENSAYOS CONTROLADOS ALEATORIZADOS  \n \nRothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short -term effects of daily \naspirin on cancer incidence, mortality, and non -vascular death: analysis of the time course of risks and benefits in \n51 randomised controlled trials. Lancet . 2012 ; 379: 1602 -1612 [M,II]  \n22440946   R/C \nEFECTOS A CORTO PLAZO DE LA ASPIRINA DIARIA SOBRE LA INCIDENCIA DE C\u00c1NCER, MORTALIDAD Y \nMUERTE NO VASCULAR: AN\u00c1LISIS DEL CURSO A LO LARGO DEL TIEMPO DE LOS RIESGOS Y LOS \nBENEFICIOS EN 51 ENSAYOS CONTROLADOS ALEATORIZADOS  \n \nHughes K, Bellis M A, Jones L, Wood S, Bates G, Eckley L, et al. Prevalence and risk of violence against adults \nwith disabilities: a systematic review and meta -analysis of observational studies. Lancet . 2012;  379: 1621 -1629 \n[M,II]     22377290   R/C \nPREVALENCIA Y RIESGO DE VIOLENCIA CONTRA ADULTOS CON DISCAPACIDADES: REVISI\u00d3N \nSISTEM\u00c1TICA Y METAAN\u00c1LISIS DE ESTUDIOS OBSERVACIONALES  \n \nSawyer SM, Afifi RA, Bearinger LH, Blakemore SJ, Dick B, Ezeh AC, et al. Adolescence: a foundation for future \nhealth. Lancet . 2012;  379: 1630 -1640 [R,I]  \n22538178   R/C \nADOLESCENCIA: CIMIENTOS DE LA SALUD FUTURA  \n \nViner RM, Ozer EM , Denny S, Marmot M, Resnick M, Fatusi A, et al. Adolescence and the social determinants of \nhealth. Lancet . 2012;  379: 1641 -1652 [R,I]  \n22538179   R/C \nADOLESCENCIA Y DE TERMINANTES SOCIALES DE LA SALUD  \n \nCatalano RF, Fagan AA, Gavin LE, Greenberg MT, Irwin CE Jr, Ross DA, et al. Worldwide application of \nprevention science in adolescent health. Lancet . 2012;  379: 1653 -1664 [R,I]  \n22538180   R/C \nAPLICACI\u00d3N MUNDIAL DE LA CIENCIA DE LA PREVENCI\u00d3N EN LA SALUD DEL ADOLESCENTE  \n \nLim LS, Mitchell P, Seddon JM, Holz FG, Wong TY . Age -related macular degeneration. Lancet . 2012; 379:  1728 -\n1738 [AO,I]  \nDEGENERACI\u00d3N MACULAR RELACIONADA CON LA EDAD  \n \nMorgan IG, Ohno -Matsui K, Saw SM. Myopia. Lancet . 2012;  379: 1739 -1748 [R,I]  \n22559900   R/C \nMIOP\u00cdA  \n \nCaritis SN, Simhan H . Cervical pessary use and preterm birth: how little we know. Lancet . 2012;  379: 1769 -1770 \n[AO,I]  \n22475492   \nUSO DE PESARIO CERVICAL Y PARTO PREMATURO: QU\u00c9 POCO CONOCEMOS  \n \nTempleton A. Misoprostol for all women seeking abortion? Lancet . 2012;  379: 1772 -1773 [AO,I]  \n22405253   \n\u00bfMISOPROSTOL PARA TODAS LAS MUJERES QUE BUSCAN ABORTAR?  \n \nGoya M, Pratcorona L, Merced C, Rod\u00f3 C, Valle L, Romero A, et  al; Pesario Cervical para Evitar Prematuridad \n(PECEP) Trial Group.  Cervical pessary in pregnant women with a short cervix (PECEP): an open -label \nrandomised controlled trial. Lancet . 2012;  379: 1800 -1806  \n[EC,I]  \n22475493   R/C \nPESARIO CERVICAL EN MUJERES EMBARAZADAS CON C\u00c9RVIX CORTO: ENSAYO CONTROLADO \nALEATORIZADO NO ENMASCARADO  \n \nChronic disease management in ageing populations. Lancet . 2012;  379: 1851 [AO,I]  \n22608320   \nMANEJO DE LA ENFERMEDAD CR\u00d3NICA EN POBLACIONES ENVEJECIDAS  \n \nTobacco industry versus tobacco control. Lancet . 2012;  379: 1924 [AO,I]  \n2263 3021   \nINDUSTRIA DEL TABACO FRENTE A CONTROL DEL TABACO  \n \nLangguth B. Tinnitus: the end of therapeutic nihilism. Lancet . 2012;  379: 1926 -1928 [AO,I]  \n22633023   \nAC\u00daFENOS: FIN DEL NIHILISMO TERAP\u00c9UTIC O \n \nTHE NEW ENGLAND JOURNAL OF MEDICINE  \n \nLamas D, Rosenbaum L. Freedom from the tyranny of choice --teaching the end -of-life conversation. N Engl J \nMed. 2012;  366: 1655 -1657 [AO,I]  \n22551124  \nLIBERARS E DE LA TIRAN\u00cdA DE ELEGIR -- ENSE\u00d1AR LA CONVERSACI\u00d3N DEL FINAL DE LA VIDA  \n    Alexander EK, Larsen PR. Radioiodine for thyroid cancer --is less more? N Engl J Med . 2012;  366: 1732 -1733 \n[AO,I]  \n22551133  \nRADIOYODO EN EL C\u00c1NCER DE TIROIDES -- \u00bfMENOS ES M\u00c1S?  \n \nRay WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J \nMed. 2012;  366: 1881 -1890 [S,I]  \n22591294  R/C \nAZITROMICINA Y RIESGO DE MUERTE CARDIOVASCULAR  \n \nFreedman ND, Park Y , Abnet CC, Hollenbeck AR, Sinha R. Association of coffee drinking with total and cause -\nspecific mortality. N Engl J Med . 2012;  366: 1891 -1904 [S,I ] \n22591295  R/C \nASOCIACI\u00d3N ENTRE BEBER CAF\u00c9 Y MORTALIDAD TOTAL Y POR CAUSAS ESPEC\u00cdFICAS  \n \nDavis SM, Donnan GA. Clinical practice. Secondary prevention after ischemic st roke or transient ischemic attack. \nN Engl J Med . 2012;  366: 1914 -1922 [R,I]  \n22591297  \nPR\u00c1CTICA CL\u00cdNICA.  PREVENCI\u00d3N SECUNDARIA TRAS ICTUS ISQU\u00c9MICO O ATAQUE ISQU\u00c9MICO \nTRANSITORIO  \n \nEikelboom JW, Conn olly SJ. Warfarin in heart failure. N Engl J Med . 2012;  366: 1936 -1938 [AO,I]  \n22551103  \nWARFARINA EN LA INSUFICIENCIA CARDIACA  \n \nGhorob A, Bodenheimer T. Sharing the care to improve access to primar y care. N Engl J Med . 2012;  366: 1955 -\n1957 [AO,I]  \n22621625  \nCOMPARTIR LA ATENCI\u00d3N PARA MEJORAR EL ACCESO A LA ATENCI\u00d3N PRIMARIA  \n \nBecattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Siling ardi M, et al; WARFASA Investigators. Aspirin \nfor preventing the recurrence of venous thromboembolism. N Engl J Med . 2012;  366: 1959 -1967 [EC,II]  \n22621626  R/C \nASPIRIN A PARA PREVENIR LA RECURRENCIA DEL TROMBOEMBOLISMO VENOSO  \n \nBecker RC. Aspirin and the prevention of venous thromboembolism. N Engl J Med . 2012;  366: 2028 -2030 [AO,I]  \n22621631  \nASPIRINA Y PREVENCI\u00d3N   DEL TROMBOEMBOLISMO VENOSO  \n \nWhitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis --where do we go from here? N Engl J \nMed. 2012;  366: 2048 -2051 [AO,I]  \n22571168  \nBIFOSFONATOS PARA  LA OSTEOPOROSIS \u00bfA D\u00d3NDE VAMOS DESDE AQU\u00cd?  \n \nBlack DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for \nosteoporosis --for whom and for how long? N Engl J Med . 2012;  366: 2051 -2053 [AO,I]  \n22571169  \nCONTINUACI\u00d3N DEL TRATAMIENTO CON BIFOSFONATOS PARA LA OSTEOPOROSIS \u00bfPARA QUI\u00c9N Y \nDURANTE CU\u00c1NTO TIEMPO?  \n \nTHORAX  \n \nPeake MD. Should we be pursuing the earlier diagnosis of lung cancer in symptomatic patients? Thorax . 2012 ; \n67: 379-380 [AO,I]  \n22426900  \n\u00bfDEBER\u00cdAMOS PERSEGUIR EL DIAGN\u00d3STICO M\u00c1S PRECOZ DEL C\u00c1NCER DE PULM\u00d3N EN PACIENTES \nSINBTOM\u00c1TICOS?  \n \nAthey VL, Suckling RJ, Tod AM, Walters SJ, Rogers TK. Early diagnosi s of lung cancer: evaluation of a \ncommunity -based social marketing intervention. Thorax . 2012;  67: 412-417 [QE,I]  \n22052579  R/C \nDIAGN\u00d3STICO PRECOZ DE C\u00c1NCER DE PULM\u00d3N:  EVALUACI\u00d3N DE UNA INTERVENCI\u00d3N DE \nMARKETING SOCIAL COMUNITARIO      \nANNALS OF INTERNAL MEDICINE  \n \nS22586006  \nA CCMP in patients with severe COPD had not decreased COPD -related hospitalizations when the trial was \nstopped prematurely. The CCMP was associated with  unanticipated excess mortality, results that differ markedly \nfrom similar previous trials. A data monitoring committee should be considered in the design of clinical trials \ninvolving behavioral interventions.  \nS22547473  \nExtremely dense breasts and first -degree relatives with breast cancer were each associated with at least a 2 -fold \nincrease in risk for breast cancer in women aged 40 to 49 years. Identification of these risk factors may be useful \nfor personalized mammography screening.  \nS22586009  \nMost studies  that are cited for the risk for CRC when relatives have adenomas do not address the issue. The 2 \nstudies that do address the issue suggest an increased risk but have important methodological limitations. \nProperly designed studies are needed to measure the  risk and identify the factors that modify it.  \nS22412038  \nCompared with LMWH, lower doses of oral factor Xa inhibitors can achieve a small absolute risk reduction in \nsymptomatic deep venous thrombosis without increasing bleeding.  \nS22547472  \nThreshold concent rations of 25 -(OH)D associated with increased risk for relevant clinical disease events center \nnear 50 nmol/L (20 ng/mL). Season -specific targets for 25 -(OH)D concentration may be more appropriate than \nstatic targets when evaluating health risk  \nS22547470  \nWomen aged 40 to 49 years with a 2 -fold increased risk have similar harm -benefit ratios for biennial screening \nmammography as average -risk women aged 50 to 74 years. Threshold RRs required for favorable harm -benefit \nratios vary by screening method, interval , and outcome measure.  \n \n \nACADEMIC MEDICINE  \n \nS22450184  \nThe Accreditation Council for Continuing Medical Education mandates that continuing medical education (CME) \nbe developed around professional practice gaps. Accordingly, CME course directors must identi fy the intended \nlearners, assess learners' needs, identify gaps in knowledge, and evaluate their CME activities. Writing gap \nstatements is challenging for CME course directors because there is not a universally accepted format for writing \nthese statements.  The authors describe a practical approach to defining gaps for CME accreditation, which \ninvolves four steps indicated by the mnemonic LASO (learner, assessment, standard, outcomes): (1) define the \nlearner population's characteristics, (2) create a learnin g needs assessment, (3) determine if the standard is met, \nand (4) state educational outcome for the CME activity. Based on this model, the difference between the practice \nstandard and the current practice represents the gap in practice. The LASO approach h as assisted in making \nCME content learner centered, relevant, and measurable at the authors' institution. The authors anticipate that \nLASO will be able to provide all CME course directors with a practical approach to defining educational gaps for \nCME accre ditation.  \nS22450183  \nThe 2002 reformatting of the standards enhanced the clarity of each standard and connected previously existing \nannotations to their standards. As a result of the reformatting, all documents and communications to schools were \ndirectly tied to specific standards. This has allowed the LCME to more easily identify areas of chronic \nnoncompliance and to improve survey team training. The shift in patterns of standards out of compliance in the \nmore recent time period is consistent with the eff ect of the reformatting. There may be other contributing factors \nfor the increase in severe action decisions, but it is clear that the reformatting of standards has improved the \nLCME's ability to monitor medical education programs.  \n \nARTHRITIS AND RHEUMATIS M \n \nS22135156  \nThe present longitudinal study revealed a high incidence of radiographic knee OA in Japan.  \nS22139828  \nOur findings indicate that patients with erosive OA have more functional impairment and significantly more pain \ncompared to patients with co ntrolled inflammatory arthritis affecting the hands. This highlights the significant \nclinical burden of erosive OA and warrants the search for new treatment strategies.  \nS22287295     Our findings, in one of the largest studies to systematically assess lumbar disc degeneration on MRI, indicated a \nsignificant association between the presence, extent, and global severity of disc degeneration with weight in \noverweight and obese adults.  \nS22139851  \nOur findings provide the first US national prevalence estimates for HLA-B27. A decline in the prevalence of HLA -\nB27 with age is suggested by these data but must be confirmed by additional studies.  \n \nARCHIVES OF INTERNAL MEDICINE  \n \nS22493407  \nOur meta -analysis showed insufficient evidence of a secondary preventive effect of o mega -3 fatty acid \nsupplements against overall cardiovascular events among patients with a history of cardiovascular disease.  \n \nARCHIVOS DE BRONCONEUMOLOGIA  \n \nS22364671  \nEn este art\u00edculo revisamos primero por pruebas (espirometr\u00eda, prueba de reversibilidad, f lujo espiratorio pico, \nvol\u00famenes pulmonares, presiones respiratorias m\u00e1ximas, transferencia de mon\u00f3xido de carbono, gasometr\u00eda \narterial, prueba de marcha de 6min y desaturaci\u00f3n con ejercicio y ergoespirometr\u00eda), y luego por patolog\u00edas m\u00e1s \nfrecuentes (disne a no aclarada, tos cr\u00f3nica, asma, EPOC, enfermedades neuromusculares, enfermedades \nintersticiales, enfermedades vasculares pulmonares, valoraci\u00f3n preoperatoria y valoraci\u00f3n de la discapacidad), la \nutilidad de las pruebas funcionales respiratorias m\u00e1s habit uales desde la perspectiva de la toma de decisiones, \nde la interpretaci\u00f3n cl\u00ednica o de aspectos que el cl\u00ednico debe tener en cuenta a la hora de utilizarlas. En \nconsecuencia, no se incide en aspectos de calidad, de la t\u00e9cnica ni de los equipos, salvo refer encia a los costos, \nporque pensamos que es un elemento importante en la toma de decisiones. El documento est\u00e1 ampliamente \nfundamentado con referencias a la literatura.  \n \nATENCION PRIMARIA  \n \nS22221963  \nLos resultados de este estudio permiten hacer una cr\u00edtica  constructiva sobre el papel del m\u00e9dico en atenci\u00f3n \nprimaria, valorar las ventajas y replantearnos los inconvenientes relacionados con nuestra forma de trabajar con \nel fin de aprender de otros sistemas organizativos.  \nS21955598  \nTras la validaci\u00f3n ling\u00fc\u00edsti ca del IPQ -Re y del BIPQ, se obtuvieron versiones conceptual y ling\u00fc\u00edsticamente \nequivalentes a los cuestionarios originales.  \nS21924796  \nCreemos que un sistema de vigilancia sindr\u00f3mica, basado en la historia electr\u00f3nica de atenci\u00f3n primaria, permite \nacceder  en tiempo real a la informaci\u00f3n, muy \u00fatil especialmente en los per\u00edodos de elevada incidencia de gripe \ncomo los per\u00edodos epid\u00e9micos o la pasada pandemia.  \nS21733598  \nEl accidente se produjo, fundamentalmente, en el hogar, en d\u00eda laborable y como consecuenc ia de ca\u00eddas. Los \ngrupos de edad m\u00e1s afectados fueron los menores de 15 a\u00f1os y = 65 a\u00f1os.  \n \nBRITISH JOURNAL OF PSYCHIATRY  \n \nS22550328  \nMindfulness -based cognitive therapy (MBCT) was developed as a psychological approach for people at risk for \ndepressive rela pse who wish to learn how to stay well in the long -term. In this article we set out the rationale for \nMBCT, outline the treatment approach, overview the efficacy research to date and look to future challenges  \nS22442102  \nEmails promoting self -help strategie s were beneficial. Internet delivery of self -help messages affords a low -cost, \neasily disseminated and highly automated approach for indicated prevention of depression.  \n \nBRITISH MEDICAL JOURNAL  \n \nS22539176  \nPrevention of non -suicidal self injury in young ado lescents should focus on helping bullied children to cope more \nappropriately with their distress. Programmes should target children who have additional mental health problems, \nhave a family history of attempted/completed suicide, or have been maltreated by  an adult.  \nS22628003  \nSeveral risk prediction models for cardiovascular disease are available and their head to head comparisons would \nbenefit from standardised reporting and formal, consistent statistical comparisons. Outcome selection and \noptimism biases apparently affect this literature.  \nS22563098     This meta -analysis -which included all trials published to date, focused on events occurring during drug exposure, \nand analysed findings using four summary estimates -found no significant increase in cardiovascula r serious \nadverse events associated with varenicline use. For rare outcomes, summary estimates based on absolute \neffects are recommended and estimates based on the Peto odds ratio should be avoided.  \nS22491789  \nAntibiotics are both effective and safe as prim ary treatment for patients with uncomplicated acute appendicitis. \nInitial antibiotic treatment merits consideration as a primary treatment option for early uncomplicated appendicitis.  \nS22551713  \nThis large cohort study found no evidence of an increased risk  of fetal death associated with exposure to an \nadjuvanted pandemic A/H1N1 2009 influenza vaccine during pregnancy.  \nS22517917  \nSPARX is a potential alternative to usual care for adolescents presenting with depressive symptoms in primary \ncare settings and cou ld be used to address some of the unmet demand for treatment.  \n \nCANADIANMEDICAL ASSOCIATIONB JOURNAL  \n \nS22470169  \nPeople using oral bisphosphonates for the first time may be at a higher risk of scleritis and uveitis compared to \npeople with no bisphosphonate u se. Patients taking bisphosphonates must be familiar with the signs and \nsymptoms of these conditions, so that they can immediately seek assessment by an ophthalmologist.  \nS22451686  \nNegative responses to both of the case -finding questions showed acceptable a ccuracy for ruling out perinatal \ndepression. For positive responses, the use of a third question about the need for help improved specificity and \nthe ability to rule in depression.  \n \nCIRCULATION  \n \nS22456473  \nIn a middle -aged community sample, we identified mu ltiple biomarkers that were associated with clinical and \nsubclinical vascular brain injury and could improve risk stratification.  \nS22514252  \nIn almost all patients with atrial fibrillation, the risk of ischemic stroke without anticoagulant treatment is high er \nthan the risk of intracranial bleeding with anticoagulant treatment. Analysis of the net benefit indicates that more \npatients may benefit from anticoagulant treatment.  \nS22539783  \nIn a population at 2% average coronary event risk per year, cholesterol, a polipoprotein, and particle measures of \nLDL were strongly correlated and had similar predictive values for incident major occlusive vascular events. It is \nunclear whether the associations between HDL particle numbers and other cardiac events represent a ca usal or \nreverse -causal effect.  \nS22514251  \nA link between oral health and cardiovascular disease has been proposed for more than a century. Recently, \nconcern about possible links between periodontal disease (PD) and atherosclerotic vascular disease (ASVD) h as \nintensified and is driving an active field of investigation into possible association and causality. The 2 disorders \nshare several common risk factors, including cigarette smoking, age, and diabetes mellitus. Patients and \nproviders are increasingly pres ented with claims that PD treatment strategies offer ASVD protection; these claims \nare often endorsed by professional and industrial stakeholders. The focus of this review is to assess whether \navailable data support an independent association between ASVD and PD and whether PD treatment might \nmodify ASVD risks or outcomes. It also presents mechanistic details of both PD and ASVD relevant to this topic. \nThe correlation of PD with ASVD outcomes and surrogate markers is discussed, as well as the correlation of  \nresponse to PD therapy with ASVD event rates. Methodological issues that complicate studies of this association \nare outlined, with an emphasis on the terms and metrics that would be applicable in future studies. Observational \nstudies to date support an as sociation between PD and ASVD independent of known confounders. They do not, \nhowever, support a causative relationship. Although periodontal interventions result in a reduction in systemic \ninflammation and endothelial dysfunction in short -term studies, the re is no evidence that they prevent ASVD or \nmodify its outcomes.  \n \nDIABETES CARE  \n \nS22410812  \nDM and higher levels of HbA(1c) were associated with lower prevalence of GI symptoms but higher prevalence of \nendoscopic abnormalities.  \nS22517938  \nOur results indicat e a bidirectional association between depression and MetS. These results support early \ndetection and management of depression among patients with MetS and vice versa.  \nS22374636     Interrupting sitting time with short bouts of light - or moderate -intensity wal king lowers postprandial glucose and \ninsulin levels in overweight/obese adults. This may improve glucose metabolism and potentially be an important \npublic health and clinical intervention strategy for reducing cardiovascular risk.  \nS22432105  \nWith intensific ation of traditional therapies, glycemic control deteriorated very little over 5 years in a large cohort of \ntype 2 diabetes. However, the requirement for insulin therapy doubled, at the expense of significant weight gain \nand risk of hypoglycemia.  \nS22456865  \nHbA(1c) trajectory increased sharply after gradual long -term increases in diabetic individuals.  \nS22446177  \nThis study demonstrates that the combination of diabetes and impaired HRF is associated with substantially \nhigher CVD mortality. This suggests that,  among those with diabetes, impaired HRF is likely to be important in the \nidentification of individuals at increased risk of CVD mortality.  \nS22399700  \nA short 30 -min session of moderate -intensity endurance -type exercise substantially reduces the prevalence of \nhyperglycemia throughout the subsequent day in type 2 diabetic patients. When total work is being matched, daily \nexercise does not further improve daily glycemia compared with exercise performed every other day.  \nS22399697  \nOptimal 25(OH)D levels substant ially lowered all -cause and cardiovascular disease mortality in subjects with the \nmetabolic syndrome. These observations call for interventional studies that test whether vitamin D \nsupplementation provides a useful adjunct in reducing mortality in these su bjects.  \n \nDRUGS  \n \nS22564130  \nDespite well known complications, oral nonsteroidal anti -inflammatory drugs (NSAIDs) remain the most commonly \nprescribed medications in the US for musculoskeletal disorders such as osteoarthritis. Although there has been a \nrecent  focus on the cardiovascular and renal complications associated with these agents, NSAID gastropathy \ncontinues to be a particular concern in many patients, especially those at increased risk for serious adverse \nevents, including the elderly. Complicating t he diagnosis of NSAID gastropathy is its silent course, which, up to \nhalf of the time, is asymptomatic. Several strategies are currently employed by physicians to mitigate the risk of \nserious gastrointestinal events. These include either addition of a prot on pump inhibitor to current nonselective \nNSAID therapy or the use of a cyclo -oxygenase -2-selective NSAID. Although these agents are effective at \nmitigating the overall risk of gastrointestinal adverse events, they fail to address NSAID -related cardiovascu lar \nand renal risks. Due to their reduced systemic absorption, topical NSAIDs may present a viable option for patients \nat increased risk for serious NSAID -related adverse events, including gastropathy.  \nS22564131  \nPaediatric obsessive -compulsive disorder (O CD) is a common, yet under -recognized, neuropsychiatric illness in \nboth clinical and community settings. Symptoms tend to be hidden or misunderstood by affected youth, and \nparents may inadvertently accommodate OCD, thus worsening its severity. These sympto ms may include \ncompulsive reassurance seeking, confessing and 'just right' rituals, in addition to more classic OCD behaviours. \nFortunately, numerous psychometric measures are available to assist in clinical assessment of this disorder and \nits sequelae. On ce properly diagnosed, paediatric OCD is highly treatable with empirically proven approaches \nincluding cognitive -behaviour therapy (CBT) and serotonin reuptake inhibitor (SRI) medications. Clinically \nmeaningful symptom improvement is the norm following the se strategies, although full remission is not, as \nsymptoms tend to wax and wane over time. Paediatric OCD is highly co -morbid with other anxiety disorders, tic \ndisorders, depression and attention -deficit hyperactivity disorder, which also require specific attention. For \nmoderate to severe OCD, an interdisciplinary approach combining individual and family CBT with SRI trials is \nrecommended. For severe treatment -refractory illness, early evidence supports the benefit of augmenting agents, \nsuch as atypical ant ipsychotics and potentially those with glutamatergic activity. Clinical outcome assessment in \npaediatric OCD should always include broad domains of individual and family functioning, in addition to symptom \nimprovement.  \n \nEUROPEAN HEART JOURNAL  \n \nS22408036  \nNon-alcoholic fatty liver disease (NAFLD) affects up to a third of the population worldwide and may confer \nincreased cardiometabolic risk with consequent adverse cardiovascular outcomes independent of traditional \ncardiovascular risk factors and the metabolic  syndrome. It is characterized almost universally by insulin resistance \nand is strongly associated with type 2 diabetes and obesity. Non -alcoholic fatty liver disease is a marker of \npathological ectopic fat accumulation combined with a low -grade chronic in flammatory state. This results in \nseveral deleterious pathophysiological processes including abnormal glucose, fatty acid and lipoprotein \nmetabolism, increased oxidative stress, deranged adipokine profile, hypercoaguability, endothelial dysfunction, \nand ac celerated progression of atherosclerosis. This ultimately leads to a dysfunctional cardiometabolic \nphenotype with cardiovascular mortality representing the main mode of premature death in NAFLD. This review is    aimed at introducing NAFLD to the clinical car diologist by discussing in -depth the evidence to date linking NAFLD \nwith cardiovascular disease, reviewing the likely mechanisms underlying this association, as well as summarizing \nfrom a cardiologist's perspective, current and potential future treatment o ptions for this increasingly prevalent \ndisease  \nS22507981  \nEvidence assembled in this review indicates that sympathetic nervous system dysfunction is crucial in the \ndevelopment of heart failure and essential hypertension. This takes the form of persistent an d adverse activation \nof sympathetic outflows to the heart and kidneys in both conditions. An important goal for clinical scientists is \ntranslation of the knowledge of pathophysiology, such as this, into better treatment for patients. The achievement \nof thi s 'mechanisms to management' transition is at different stages of development with regard to the two \ndisorders. Clinical translation is mature in cardiac failure, knowledge of cardiac neural pathophysiology having led \nto the introduction of beta -adrenergic  blockers, an effective therapy. With essential hypertension perhaps we are \non the cusp of effective translation, with recent successful testing of selective catheter -based renal sympathetic \nnerve ablation in patients with resistant hypertension, an interv ention firmly based on the demonstration of \nactivation of the renal sympathetic outflow. Additional evidence in this regard is provided by the results of pilot \nstudies exploring the possibility to reduce blood pressure in resistant hypertensives through el ectrical stimulation \nof the area of carotid baroreceptors. Despite the general importance of the sympathetic nervous system in blood \npressure regulation, and the specific demonstration that the blood pressure elevation in essential hypertension is \ncommonly  initiated and sustained by sympathetic nervous activation, drugs antagonizing this system are currently \nunderutilized in the care of patients with hypertension. Use of beta -adrenergic blocking drugs is waning, given the \npropensity of this drug class to ha ve adverse metabolic effects, including predisposition to diabetes development. \nThe blood pressure lowering achieved with carotid baroreceptor stimulation and with the renal denervation device \naffirms the importance of the sympathetic nervous system in hyp ertension pathogenesis, and perhaps suggests a \nwider role for anti -adrenergic antihypertensives, such as the imidazoline drug class (moxonidine, rilmenidine) \nwhich act within the CNS to inhibit central sympathetic outflow, although the lack of large -scale outcome trials with \nthis drug class remains a very material deficiency.  \nS22408030  \nThis raises the question of whether the Cardiological community dismissed digoxin too readily and if we should \nreappraise its potential role in the treatment of heart failure  \n \nFAMILY MEDICINE  \n \nAccepting gifts from the pharmaceutical industry has implications for the doctor -patient relationship. Doing so can \nundermine trust and affect patients\u2019 intent to adhere to medical  \nrecommendations.  \n \nAn intervention using a learning coach  to provide one -on-one EBM and information mastery instruction to \nresidents improved residents\u2019 attitudes, knowledge, and use of both in the clinical setting.  \n \nInternet use was high among our primary care patients. The major factor associated with Internet  use among \npatients with chronic conditions was their age. If older adults with  \nchronic illness are to reap the benefits of health information technology, their Internet access will need to be \nimproved. Institutions that are planning to offer consumer heal th information technology should be aware of \ngroups with lower Internet access.  \n \nGUT  \n \nS22491499  \nManagement of Helicobacter pylori infection is evolving and in this 4th edition of the Maastricht consensus report \naspects related to the clinical role of H pyl ori were looked at again in 2010. In the 4th Maastricht/Florence \nConsensus Conference 44 experts from 24 countries took active part and examined key clinical aspects in three \nsubdivided workshops: (1) Indications and contraindications for diagnosis and tre atment, focusing on dyspepsia, \nnon-steroidal anti -inflammatory drugs or aspirin use, gastro -oesophageal reflux disease and extraintestinal \nmanifestations of the infection. (2) Diagnostic tests and treatment of infection. (3) Prevention of gastric cancer an d \nother complications. The results of the individual workshops were submitted to a final consensus voting to all \nparticipants. Recommendations are provided on the basis of the best current evidence and plausibility to guide \ndoctors involved in the manageme nt of this infection associated with various clinical conditions.  \n \nJOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE  \n \nS22570392  \nComprehensive primary care mental health screening that considers both anxiety and depression while including \nstrength -based and  psychosocial support questions is a helpful adjunct to clinical practices and has been done \nroutinely by using an electronic tool at the point of care. Because certain common somatic and emotional    concerns can precede depression and anxiety, routine scree ning for these issues along with depression and \nanxiety screening is suggested.  \nS22570399  \nFamily physicians play a crucial role in the management and ongoing care of patients with Alzheimer disease \n(AD). This article reviews the effects of nonpharmacologi c and pharmacologic interventions on the functional \nabilities and behavior of patients with dementia and how these can be implemented into clinical practice. \nNonpharmacologic interventions are recommended as the initial strategy for managing problematic be haviors. \nStrategies for improving behavior include ensuring that the patient's environment is safe, calm, and predictable; \nremoving environmental stressors; and identifying and avoiding situations that agitate or frighten the patient. \nSimple interventions include redirecting and refocusing the patient, increasing social interaction, establishing \nregular sleep habits, eliminating sources of conflict and frustration, and establishing rewards for successes. The \neffectiveness of long -term behavioral management is largely dependent on the caregiver; as such, it is important \nto assess the role and needs of the caregiver. Because currently available therapies cannot reverse the \npathologic processes of AD, the primary objective of pharmacotherapy is to preserve cogn itive and functional \nability, minimize behavioral disturbances, and slow disease progression. Cholinesterase inhibitors represent first -\nline therapy for patients with mild to moderate AD, whereas a glutamate N -methyl D -aspartate antagonist is used \nin the t reatment of moderate to severe AD. Looking forward, there are a number of therapies in development \naimed at modifying the disease course; these include amyloid -lowering drugs, t -based and neuroprotective \napproaches, acetylcholine agonists, and mitochondria l inhibitors.  \nS22570400  \nTo date, user -friendly, practical guidelines for dementia have not been available for busy family physicians. \nHowever, the growing number of patients with dementia means that primary care physicians will have an \nincreasingly import ant role in the diagnosis and subsequent management of dementia. This article provides \npractical guidance for the recognition and diagnosis of dementia and is aimed at family physicians, who are \nusually the first clinicians to whom patients present with de mentia symptoms. Because Alzheimer disease (AD) is \nthe most common form of dementia, this condition is the main focus of this article. We review the pathophysiology \nof AD and discuss recommended diagnostic protocols and the importance of early diagnosis. A n AD diagnostic \nalgorithm is provided, with clearly defined steps for screening and diagnosing AD and assessing daily functioning, \nbehavioral symptoms, and caregiver status.  \n \nMEDICINA CLINICA  \n \nS22397982  \nLa anemia supone un mayor riesgo de mortalidad por I C refractaria, pero no de reingreso, en el primer a\u00f1o tras \nuna descompensaci\u00f3n aguda.  \nS22503128  \nEn el presente documento se pretende adaptar las recomendaciones generales establecidas en un consenso \npara la elaboraci\u00f3n del informe de alta hospitalaria en especialidades m\u00e9dicas a las necesidades espec\u00edficas de \nla poblaci\u00f3n diab\u00e9tica hospitalizada. La diabetes es una enfermedad con un coste sanitario muy elevado, siendo \nel riesgo global de muerte entre personas con diabetes casi el doble que entre personas s in diabetes, lo que \njustifica que esta patolog\u00eda constituya uno de los diagn\u00f3sticos m\u00e1s frecuentes en los pacientes hospitalizados y el \ncreciente inter\u00e9s sobre el tratamiento de la hiperglucemia durante la hospitalizaci\u00f3n y al alta. Para establecer un \nplan de tratamiento al alta adecuado a cada paciente, los elementos m\u00e1s importantes a tener en cuenta son la \netiolog\u00eda y el tratamiento previo de la hiperglucemia, la situaci\u00f3n cl\u00ednica del paciente y el grado de control \ngluc\u00e9mico. Debido a la inestabilidad del  control gluc\u00e9mico tambi\u00e9n es necesario prever las necesidades \neducativas de cada paciente, as\u00ed como establecer las pautas de monitorizaci\u00f3n y seguimiento al alta, y un \nadecuado plan de tratamiento al alta.  \nS22015005  \nSe realiz\u00f3 una revisi\u00f3n sistem\u00e1tica de  art\u00edculos cient\u00edficos y estudios de instituciones oficiales europeas. En total, \nfueron identificados 21 art\u00edculos y 10 estudios. Los datos sugieren un aumento de la iniciaci\u00f3n sexual juvenil y del \nn\u00famero de parejas sexuales. El 15 -20% de los j\u00f3venes usan de forma inconstante el preservativo. Entre los \nconocimientos y actitudes de riesgo detectadas encontramos: desconocer otras ITS distintas al VIH, tener una \nactitud favorable a las relaciones sexuales casuales, creer err\u00f3neamente que algunas medidas son ef icaces para \nprevenir el VIH, desconocer los riesgos de tener m\u00faltiples parejas sexuales y desconocer la transmisi\u00f3n sexual \ndel VIH.  \nS21663923  \nTras el diagn\u00f3stico inicial de la IC, m\u00e1s de la mitad de los pacientes fallecen a los 10 a\u00f1os de seguimiento. La \nedad, la diabetes mellitus, la cardiopat\u00eda isqu\u00e9mica y la insuficiencia renal cr\u00f3nica se asocian a un peor \npron\u00f3stico en estos pacientes, mientras que el uso de betabloqueantes se asocia a un mejor pron\u00f3stico.  \nS22118974  \nSe constata el deterioro del contro l gluc\u00e9mico con la evoluci\u00f3n de la enfermedad y la complejidad del proceso y \ndel tratamiento, lo que en parte puede estar relacionado con la inadecuada selecci\u00f3n e intensificaci\u00f3n del \ntratamiento.  \nS22153783     La implantaci\u00f3n del CI es un sistema que mejor\u00f3 la atenci\u00f3n precoz del ictus en todo el territorio, pero su \nactivaci\u00f3n en el \u00e1mbito de atenci\u00f3n primaria fue baja.  \nS22440145  \nUse of AOBP devices can contribute to decrease WCE and to improve accuracy of office BP measurement.  \nS21944650  \nM\u00e1s de 5 de cada 1 0 mujeres hipertensas mayores de 64 a\u00f1os presentan ERC, y de estas casi la mitad tienen \nvalores de creatinina normales.  \n \n \nREUMATOLOGIA CLINICA  \n \nS22089065  \nEn la actualidad, la determinaci\u00f3n de marcadores bioqu\u00edmicos de remodelado \u00f3seo supone una propuesta \nnovedosa en la evaluaci\u00f3n cl\u00ednica de los pacientes con osteoporosis. El uso de estos biomarcadores podr\u00eda \npermitir la identificaci\u00f3n de pacientes con mayor riesgo de fractura y monitorizar la respuesta terap\u00e9utica. Al \ntratarse de mediciones no invasivas y relativamente econ\u00f3micas, deber\u00eda extenderse su empleo, ya que \nposibilitar\u00eda una medici\u00f3n seriada y en intervalos cortos de las variaciones en el recambio \u00f3seo. Sin embargo, su \nvariabilidad anal\u00edtica y biol\u00f3gica limita en la actualidad su aplicabilidad cl\u00ed nica.  \nS22421456  \nLa prevenci\u00f3n de FC con alendronato en mujeres osteopor\u00f3ticas > 64 a\u00f1os es coste -\u00fatil a largo plazo (20 a\u00f1os) \ncon bajo impacto presupuestario en el grupo de 75 -79 a\u00f1os.  \n \nTHE LANCET  \n \nS22538178  \nAdolescence is a life phase in which the oppor tunities for health are great and future patterns of adult health are \nestablished.  \nHealth in adolescence is the result of interactions between prenatal and early childhood development and the \nspecific biological and social -role changes that accompany pube rty, shaped by social determinants and risk and \nprotective factors that affect the uptake of health -related behaviours. The shape of adolescence is rapidly \nchanging -the age of onset of puberty is decreasing and the age at which mature social roles are achi eved is \nrising. New understandings of the diverse and dynamic effects on adolescent health include insights into the \neffects of puberty and brain development, together with social media. A focus on adolescence is central to the \nsuccess of many public healt h agendas, including the Millennium Development Goals aiming to reduce child and \nmaternal mortality and HIV/AIDS, and the more recent emphases on mental health, injuries, and non -\ncommunicable diseases. Greater attention to adolescence is needed within each  of these public health domains if \nglobal health targets are to be met. Strategies that place the adolescent years centre stage -rather than focusing \nonly on specific health agendas -provide important opportunities to improve health, both in adolescence and later \nin life.  \nS22538179  \nThe health of adolescents is strongly affected by social factors at personal, family, community, and national levels. \nNations present young people with structures of opportunity as they grow up. Since health and health behaviours \ncorrespond strongly from adolescence into adult life, the way that these social determinants affect adolescent \nhealth are crucial to the health of the whole population and the economic development of nations. During \nadolescence, developmental effects relat ed to puberty and brain development lead to new sets of behaviours and \ncapacities that enable transitions in family, peer, and educational domains, and in health behaviours.  \nThese transitions modify childhood trajectories towards health and wellbeing and are modified by economic and \nsocial factors within countries, leading to inequalities. We review existing data on the effects of social \ndeterminants on health in adolescence, and present findings from country -level ecological analyses on the health \nof youn g people aged 10 -24 years. The strongest determinants of adolescent health worldwide are structural \nfactors such as national wealth, income inequality, and access to education. Furthermore, safe and supportive \nfamilies, safe and supportive schools, togethe r with positive and supportive peers are crucial to helping young \npeople develop to their full potential and attain the best health in the transition to adulthood. Improving adolescent \nhealth worldwide requires improving young people's daily life with fami lies and peers and in schools, addressing \nrisk and protective factors in the social environment at a population level, and focusing on factors that are \nprotective across various health outcomes. The most effective interventions are probably structural chan ges to \nimprove access to education and employment for young people and to reduce the risk of transport -related injury.  \nS22475493  \nCervical pessary use could prevent preterm birth in a population of appropriately selected at -risk women \npreviously screened f or cervical length assessment at the midtrimester scan.  \nS22440946  \nAlongside the previously reported reduction by aspirin of the long -term risk of cancer death, the short -term \nreductions in cancer incidence and mortality and the decrease in risk of major e xtracranial bleeds with extended \nuse, and their low case -fatality, add to the case for daily aspirin in prevention of cancer.  \nS22440947     That aspirin prevents distant metastasis could account for the early reduction in cancer deaths in trials of daily \naspirin versus control. This finding suggests that aspirin might help in treatment of some cancers and provides \nproof of principle for pharmacological intervention specifically to prevent distant metastasis.  \nS22559900  \nMyopia has emerged as a major health issu e in east Asia, because of its increasingly high prevalence in the past \nfew decades (now 80 -90% in school -leavers), and because of the sight -threatening pathologies associated with \nhigh myopia, which now affects 10 -20% of those completing secondary schooli ng in this part of the world. Similar, \nbut less marked, changes are occurring in other parts of the world. The higher prevalence of myopia in east Asian \ncities seems to be associated with increasing educational pressures, combined with life -style changes, which \nhave reduced the time children spend outside. There are no reported major genes for school myopia, although \nthere are several genes associated with high myopia. Any genetic contribution to ethnic differences may be small. \nHowever, to what extent many  genes of small effect and gene -environment interactions contribute to variations in \nschool myopia within populations remains to be established. There are promising optical and pharmacological \ninterventions for preventing the development of myopia or slowi ng its progression, which require further validation, \nand promising vision -sparing treatments for pathological myopia.  \nS22377290  \nAdults with disabilities are at a higher risk of violence than are non -disabled adults, and those with mental \nillnesses could be particularly vulnerable. However, available studies have methodological weaknesses and gaps \nexist in the types of disability and violence they address. Robust studies are absent for most regions of the world, \nparticularly low -income and middle -income co untries.  \nS22377290  \nAdults with disabilities are at a higher risk of violence than are non -disabled adults, and those with mental \nillnesses could be particularly vulnerable. However, available studies have methodological weaknesses and gaps \nexist in the ty pes of disability and violence they address. Robust studies are absent for most regions of the world, \nparticularly low -income and middle -income countries.  \nS22538180  \nThe burden of morbidity and mortality from non -communicable disease has risen worldwide an d is accelerating in \nlow-income and middle -income countries, whereas the burden from infectious diseases has declined. Since this \ntransition, the prevention of non -communicable disease as well as communicable disease causes of adolescent \nmortality has rise n in importance. Problem behaviours that  increase the short -term or long -term likelihood of \nmorbidity and mortality, including alcohol, tobacco, and other drug misuse, mental health problems, unsafe sex, \nrisky and unsafe driving, and violence are largely p reventable. In the past 30 years new discoveries have led to \nprevention science being established as a discipline designed to mitigate these problem behaviours. Longitudinal \nstudies have provided an understanding of risk and protective factors across the l ife course for many of these \nproblem behaviours. Risks cluster across development to produce early accumulation of risk in childhood and \nmore pervasive risk in adolescence. This understanding has led to the construction of developmentally \nappropriate preve ntion policies and programmes that have shown short -term and long -term reductions in these \nadolescent problem behaviours. We describe the principles of prevention science, provide examples of efficacious \npreventive interventions, describe challenges and po tential solutions to take efficacious prevention policies  and \nprogrammes to scale, and conclude with recommendations to reduce the burden of adolescent mortality and \nmorbidity worldwide through preventive intervention.  \n \n \nTHE NEW ENGLAND JOURNAL OF MEDICINE  \n \nS22591295  \nIn this large prospective study, coffee consumption was inversely associated with total and cause -specific \nmortality. Whether this was a causal or associational finding cannot be determined from our data.  \nS22591294  \nDuring 5 days of azithromyc in therapy, there was a small absolute increase in cardiovascular deaths, which was \nmost pronounced among patients with a high baseline risk of cardiovascular disease  \nS22621626  \nAspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had \ndiscontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding.  \n \nTHORAX  \n \nS22052579  \nThis is encouraging early evidence that an awareness and early recognition initiative may facilitate lung cance r \ndiagnosis.  \n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}